Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. - De Santis, Maria; Palou Redorta, Joan; Nishiyama, Hiroyuki; Krawczyński, Michał; Seyitkuliev, Artur; Novikov, Andrey; Guerrero-Ramos, Félix; Zukov, Ruslan; Kato, Minoru; Kawahara, Takashi; Goeman, Lieven; Puente, Javier; et al. (Lancet, 2025)